These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38934860)

  • 41. Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt).
    Sikora JL; Logue MW; Chan GG; Spencer BH; Prokaeva TB; Baldwin CT; Seldin DC; Connors LH
    Hum Genet; 2015 Jan; 134(1):111-21. PubMed ID: 25367359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).
    Ruberg FL; Maurer MS; Judge DP; Zeldenrust S; Skinner M; Kim AY; Falk RH; Cheung KN; Patel AR; Pano A; Packman J; Grogan DR
    Am Heart J; 2012 Aug; 164(2):222-228.e1. PubMed ID: 22877808
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.
    Cappelli F; Baldasseroni S; Bergesio F; Perlini S; Salinaro F; Padeletti L; Attanà P; Paoletti Perini A; Moggi Pignone A; Grifoni E; Fabbri A; Marchionni N; Gensini GF; Perfetto F
    Clin Cardiol; 2015 Feb; 38(2):69-75. PubMed ID: 25645201
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationships between biomarkers and left ventricular filling pressures at rest and during exercise in patients after myocardial infarction.
    Andersen MJ; Ersbøll M; Bro-Jeppesen J; Møller JE; Hassager C; Køber L; Borlaug BA; Goetze JP; Gustafsson F
    J Card Fail; 2014 Dec; 20(12):959-67. PubMed ID: 25285749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
    Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
    Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hemodynamic importance of preserving the normal sequence of ventricular activation in permanent cardiac pacing.
    Leclercq C; Gras D; Le Helloco A; Nicol L; Mabo P; Daubert C
    Am Heart J; 1995 Jun; 129(6):1133-41. PubMed ID: 7754944
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment.
    Hunt PJ; Richards AM; Nicholls MG; Yandle TG; Doughty RN; Espiner EA
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):287-96. PubMed ID: 9373449
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exercise hemodynamics in patients with and without diastolic dysfunction and preserved ejection fraction after myocardial infarction.
    Andersen MJ; Ersbøll M; Bro-Jeppesen J; Gustafsson F; Hassager C; Køber L; Borlaug BA; Boesgaard S; Kjærgaard J; Møller JE
    Circ Heart Fail; 2012 Jul; 5(4):444-51. PubMed ID: 22705767
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study.
    Tini G; Milani P; Zampieri M; Caponetti AG; Fabris F; Foli A; Argirò A; Mazzoni C; Gagliardi C; Longhi S; Saturi G; Vergaro G; Aimo A; Russo D; Varrà GG; Serenelli M; Fabbri G; De Michieli L; Palmiero G; Ciliberti G; Carigi S; Sessarego E; Mandoli GE; Ricci Lucchi G; Rella V; Monti E; Gardini E; Bartolotti M; Crotti L; Merli E; Mussinelli R; Vianello PF; Cameli M; Marzo F; Guerra F; Limongelli G; Cipriani A; Perlini S; Obici L; Perfetto F; Autore C; Porto I; Rapezzi C; Sinagra G; Merlo M; Musumeci B; Emdin M; Biagini E; Cappelli F; Palladini G; Canepa M
    Eur J Heart Fail; 2023 Jun; 25(6):845-853. PubMed ID: 36907828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.
    Chamling B; Bietenbeck M; Korthals D; Drakos S; Vehof V; Stalling P; Meier C; Yilmaz A
    Clin Res Cardiol; 2023 Mar; 112(3):353-362. PubMed ID: 35666277
    [TBL] [Abstract][Full Text] [Related]  

  • 51. N-terminal pro-B-type natriuretic peptide and its relationship with cardiac function in adults with congenital heart disease.
    Eindhoven JA; van den Bosch AE; Ruys TP; Opić P; Cuypers JA; McGhie JS; Witsenburg M; Boersma E; Roos-Hesselink JW
    J Am Coll Cardiol; 2013 Sep; 62(13):1203-12. PubMed ID: 23916937
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics.
    Lele SS; Thomson HL; Seo H; Belenkie I; McKenna WJ; Frenneaux MP
    Circulation; 1995 Nov; 92(10):2886-94. PubMed ID: 7586256
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: A systematic review and meta-analysis.
    Xin Y; Hu W; Chen X; Hu J; Sun Y; Zhao Y
    Hellenic J Cardiol; 2019; 60(6):375-383. PubMed ID: 30742933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.
    Cappelli F; Martone R; Gabriele M; Taborchi G; Morini S; Vignini E; Allinovi M; Di Gioia M; Bartolini S; Di Mario C; Perfetto F
    Can J Cardiol; 2020 Mar; 36(3):424-431. PubMed ID: 32145869
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exercise dependence of N-terminal pro-brain natriuretic peptide in patients with precapillary pulmonary hypertension.
    Grachtrup S; Brügel M; Pankau H; Halank M; Wirtz H; Seyfarth HJ
    Respiration; 2012; 84(6):454-60. PubMed ID: 22327025
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy.
    Wu D; Chen W
    Heart Fail Rev; 2024 Mar; 29(2):511-521. PubMed ID: 38233673
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Elevated NT-ProBNP levels in patients with increased left ventricular filling pressure during exercise despite preserved systolic function.
    Tschöpe C; Kasner M; Westermann D; Walther T; Gaub R; Poller WC; Schultheiss HP
    J Card Fail; 2005 Jun; 11(5 Suppl):S28-33. PubMed ID: 15948097
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis.
    Annabi MS; Carter-Storch R; Zaroui A; Galat A; Oghina S; Kharoubi M; Bezard M; Derumeaux G; Fanen P; Lemonnier F; Poullot E; Itti E; Gallet R; Teiger E; Pibarot P; Damy T; Clavel MA
    J Am Heart Assoc; 2024 Jul; 13(13):e034723. PubMed ID: 38904242
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hemodynamic Profiling and Prognosis in Cardiac Amyloidosis.
    Martens P; Bhattacharya S; Longinow J; Ives L; Jacob M; Valent J; Hanna M; Tang WHW
    Circ Heart Fail; 2023 Mar; 16(3):e010078. PubMed ID: 36695180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
    Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
    Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.